{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:08Z","timestamp":1791281708028,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.beem.2023.101787","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T14:22:11Z","timestamp":1686147731000},"page":"101787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms"],"prefix":"10.1016","volume":"37","author":[{"given":"Johannes","family":"Hofland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2023.101787_bib1","series-title":"Diffuse Hormonal Systems","author":"Andersson-Rolf","year":"2000"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.beem.2023.101787_bib3","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41574-018-0082-5","article-title":"Role of biomarker tests for diagnosis of neuroendocrine tumours","volume":"14","author":"Hofland","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1210\/jc.2015-2436","article-title":"Multiple and secondary hormone secretion in patients with metastatic pancreatic neuroendocrine tumours","volume":"101","author":"Crona","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2023.101787_bib5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/M14-2132","article-title":"Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study","volume":"162","author":"de Mestier","year":"2015","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/EJE-15-0968","article-title":"Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors","volume":"174","author":"Kamp","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2023.101787_bib9","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1210\/jc.2014-1315","article-title":"Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up","volume":"99","author":"Kamp","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101787_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejca.2022.06.003","article-title":"Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study","volume":"172","author":"Polee","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2023.101787_bib11","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-18-0495","article-title":"Management of carcinoid syndrome: a systematic review and meta-analysis","author":"Hofland","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.beem.2023.101787_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/S0004-27302005000500028","article-title":"de Herder WW. Carcinoid syndrome: diagnosis and medical management","volume":"49","author":"van der Lely","year":"2005","journal-title":"Arq Bras Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11154-020-09547-8","article-title":"Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications","volume":"21","author":"Fanciulli","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"7","key":"10.1016\/j.beem.2023.101787_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocr"},{"issue":"7","key":"10.1016\/j.beem.2023.101787_bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0091270005277936","article-title":"Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles","volume":"45","author":"Astruc","year":"2005","journal-title":"J Clin Pharm"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.beem.2023.101787_bib17","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","article-title":"Refractory carcinoid syndrome: a review of treatment options","volume":"9","author":"Riechelmann","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.beem.2023.101787_bib19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.beem.2023.101787_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr-Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1634\/theoncologist.2018-0191","article-title":"Oral ondansetron offers effective antidiarrheal activity for carcinoid syndrome refractory to somatostatin analogs","volume":"24","author":"Kiesewetter","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.beem.2023.101787_bib23","doi-asserted-by":"crossref","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.beem.2023.101787_bib25","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2023.101787_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroendocrine GEP-tumors: a review","volume":"62","author":"Oberg","year":"2000","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.beem.2023.101787_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jir.2006.26.8","article-title":"Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas","volume":"26","author":"Pavel","year":"2006","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib28","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1530\/ERC-17-0380","article-title":"Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum","volume":"25","author":"Blazevic","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.beem.2023.101787_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.beem.2023.101787_bib30","first-page":"3477","article-title":"Clinical characteristics and incidences of benign and malignant insulinoma using a National Inpatient Database in Japan","volume":"106","author":"Kurakawa","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2023.101787_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000080735","article-title":"Insulinoma","volume":"80","author":"de Herder","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"12","key":"10.1016\/j.beem.2023.101787_bib32","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.hpb.2021.04.013","article-title":"Surgical management of insulinoma over three decades","volume":"23","author":"de Carbonnieres","year":"2021","journal-title":"HPB (Oxf)"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.14310\/horm.2002.1706","article-title":"Glycemic control in patients with insulinoma","volume":"15","author":"Matej","year":"2016","journal-title":"Hormones"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1507\/endocrj.EJ18-0353","article-title":"Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide","volume":"66","author":"Niitsu","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2023.101787_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13098-017-0215-3","article-title":"Characteristics of glucose metabolism indexes and continuous glucose monitoring system (CGMS) in patients with insulinoma","volume":"9","author":"Gu","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"10.1016\/j.beem.2023.101787_bib36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPA.0000000000001569","article-title":"Effectiveness of liver-directed therapy for the management of intractable hypoglycemia in metastatic insulinoma","volume":"49","author":"Habibollahi","year":"2020","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.beem.2023.101787_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/eje.1.01901","article-title":"Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies","volume":"152","author":"Vezzosi","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101787_bib38","first-page":"34","article-title":"Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin)","volume":"121","author":"Stehouwer","year":"1989","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.beem.2023.101787_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.860614","article-title":"Pasireotide for refractory hypoglycemia in malignant insulinoma- case report and review of the literature","volume":"13","author":"Oziel-Taieb","year":"2022","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/EJE-19-0989","article-title":"Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study","volume":"182","author":"Veltroni","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2023.101787_bib41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-12-1101","article-title":"Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia","volume":"168","author":"Bernard","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101787_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beem.2023.101787_bib43","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2011-1563","article-title":"Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy","volume":"96","author":"van Schaik","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2023.101787_bib44","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beem.2023.101787_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beem.2023.101787_bib46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2265.1975.tb01555.x","article-title":"Malignant metastatic insulinoma treated with streptozotocin","volume":"4","author":"Gefel","year":"1975","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.beem.2023.101787_bib47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MOG.0b013e328365efb1","article-title":"Zollinger-Ellison syndrome: recent advances and controversies","volume":"29","author":"Ito","year":"2013","journal-title":"Curr Opin Gastroenterol"},{"issue":"39","key":"10.1016\/j.beem.2023.101787_bib48","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.3748\/wjg.v18.i39.5495","article-title":"Diagnosis of Zollinger-Ellison syndrome: increasingly difficult","volume":"18","author":"Ito","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2217\/ije-2017-0018","article-title":"Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing","volume":"4","author":"Metz","year":"2017","journal-title":"Int J Endocr Oncol"},{"issue":"5","key":"10.1016\/j.beem.2023.101787_bib50","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1373\/clinchem.2011.179929","article-title":"Pitfalls in diagnostic gastrin measurements","volume":"58","author":"Rehfeld","year":"2012","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.beem.2023.101787_bib51","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.cgh.2017.09.033","article-title":"Interchangeable use of proton pump inhibitors based on relative potency","volume":"16","author":"Graham","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/01.sla.0000234802.44320.a5","article-title":"Surgery increases survival in patients with gastrinoma","volume":"244","author":"Norton","year":"2006","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"94","author":"Shojamanesh","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.beem.2023.101787_bib55","first-page":"46","article-title":"Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma","volume":"5","author":"Dumont","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archinte.1986.00360150076009","article-title":"Serum gastrin level is increased by chronic hypercalcemia of parathyroid or nonparathyroid origin","volume":"146","author":"Jordan","year":"1986","journal-title":"Arch Intern Med"},{"issue":"5B","key":"10.1016\/j.beem.2023.101787_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(87)90425-6","article-title":"VIPoma syndrome","volume":"82","author":"Krejs","year":"1987","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.beem.2023.101787_bib58","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/MPA.0000000000001402","article-title":"Vasoactive intestinal peptide-secreting tumors: a review","volume":"48","author":"Siddappa","year":"2019","journal-title":"Pancreas"},{"issue":"8","key":"10.1016\/j.beem.2023.101787_bib59","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.pan.2021.08.001","article-title":"Efficacy of treatments for VIPoma: a GTE multicentric series","volume":"21","author":"Brugel","year":"2021","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.beem.2023.101787_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pan.2018.10.007","article-title":"Pancreatic VIPomas from China: case reports and literature review","volume":"19","author":"Chen","year":"2019","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib61","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2023.101787_bib62","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.pan.2021.08.001","article-title":"Efficacy of treatments for VIPoma: a GTE multicentric series","volume":"21","author":"Brugel","year":"2021","journal-title":"Pancreatology"},{"issue":"7","key":"10.1016\/j.beem.2023.101787_bib63","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/MPA.0000000000001347","article-title":"Diagnostic and management challenges in vasoactive intestinal peptide secreting tumors: a series of 15 patients","volume":"48","author":"Angelousi","year":"2019","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib64","first-page":"53","article-title":"The glucagonoma syndrome","volume":"75","author":"Wermers","year":"1996","journal-title":"Clin Pathol Features 21 Patients Med (Baltim)"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib65","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/DAD.0000000000001219","article-title":"Glucagonoma-associated necrolytic migratory erythema: the broad spectrum of the clinical and histopathological findings and clues to the diagnosis","volume":"41","author":"Toberer","year":"2019","journal-title":"Am J Derm"},{"key":"10.1016\/j.beem.2023.101787_bib66","doi-asserted-by":"crossref","unstructured":"Gorden P., Comi R.J., Maton P.N.,\u00a0et al., NIH conference. Somatostatin and somatostatin analogue (SMS 201\u2013995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110(1):35\u201350.","DOI":"10.7326\/0003-4819-110-1-35"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12032-007-0011-2","article-title":"Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years","volume":"24","author":"Kindmark","year":"2007","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11154-018-9443-6","article-title":"Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important","volume":"19","author":"Jin","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamadermatol.2015.3538","article-title":"Rapid clearance of necrolytic migratory erythema following intravenous administration of amino acids","volume":"152","author":"Thomaidou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"9996","key":"10.1016\/j.beem.2023.101787_bib70","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.beem.2023.101787_bib71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing's syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2023.101787_bib73","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2023.101787_bib74","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing's syndrome: a real-world multicenter study in France","author":"Dormoy","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2023.101787_bib75","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4158\/EP09286.CR","article-title":"Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review","volume":"16","author":"Bruno","year":"2010","journal-title":"Endocr Pr"},{"issue":"2","key":"10.1016\/j.beem.2023.101787_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2011-1264","article-title":"Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion","volume":"97","author":"de Bruin","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2023.101787_bib77","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2023.101787_bib78","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an Endocrine Society Clinical Practice Guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2023.101787_bib79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ando.2012.09.004","article-title":"Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery","volume":"73","author":"Borson-Chazot","year":"2012","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2023.101787_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.867965","article-title":"Acromegaly caused by ectopic growth hormone releasing hormone secretion: a review","volume":"13","author":"Zendran","year":"2022","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2023.101787_bib81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1440-1746.2007.05053.x","article-title":"Somatostatinoma: clinico-pathological features of three cases and literature reviewed","volume":"23","author":"Nesi","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.beem.2023.101787_bib82","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/gut.42.6.792","article-title":"Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours","volume":"42","author":"Angeletti","year":"1998","journal-title":"Gut"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:00:47Z","timestamp":1761498047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X23000611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1521690X23000611"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101787","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101787"}}